PAVmed is a medical device company. Co.'s products include: EsoGuard, a molecular diagnostic esophageal DNA test shown in a published human study at detecting Barrett's Esophagus (BE), as well as adenocarcinoma of the esophagus (EAC); EsoCheck, a non-invasive cell collection device designed to sample cells from a targeted region of the esophagus; EsoCure, which is in development to provide an Esophageal Ablation Device using Caldus Technology to allow a clinician to treat dysplastic BE before it can progress to EAC; CarpX, a minimally invasive device designed to treat carpal tunnel syndrome; and NextFlo, an intravenous infusion set to eliminate the need for electronic infusion pumps. The PAVM stock yearly return is shown above.
The yearly return on the PAVM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PAVM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|